Picard Medical Inc

Picard Medical Inc(PMI)股票分析

$8.789

+1.051 (+11.96%)收盘时

Loading chart…
最高
9.140
开盘
7.850
成交量加权均价
8.54
成交量
44.87K
市值
—
最低
7.683
成交额
383.06K
企业价值/息税折旧摊销前利润(TTM)
-2.20

Picard Medical, Inc. is a holding company that owns a 100% interest in SynCardia Systems, LLC (SynCardia). SynCardia is a medical technology company that manufactures and sells the only United States Food and Drug Administration (FDA) and Health Canada-approved implantable total artificial heart (SynCardia TAH). The SynCardia TAH is a biventricular replacement device that consists of the SynCardia TAH implant, an external pneumatic driver that delivers precisely calibrated pulses of air to drive the implant, and drivelines that connect the driver to the implant. The SynCardia TAH implant is a system that consists of two independent artificial ventricles which are powered by an external pneumatic driver. Each artificial ventricle is made of a semi-rigid polyurethane housing and a rigid polyurethane base, with a four-layer flexible polyurethane diaphragm separating the blood chamber from the air chamber.

AI 分析 of Picard Medical Inc (PMI)

买入

Picard Medical Inc (PMI) appears to be a good buy right now due to its recent revenue growth of 39% in Q2 2026, reaching approximately $3.0 million, and a notable improvement in gross margin to 20.9%. However, the main risk is the ongoing net loss of approximately $5.7 million for the same quarter, which indicates that while the company is improving, it still faces significant financial challenges.

估值指标

Picard Medical Inc(PMI)当前预期市盈率为 0.00,5 年平均预期市盈率为 0.00。

预期市盈率

严重低估
5 年均值 P/E
0.00
当前P/E
0.00
高估
0.00
低估
0.00

预期 EV/EBITDA

低估
5 年均值 EV/EBITDA
-0.74
当前EV/EBITDA
-2.20
高估
0.15
低估
-1.62

预期市销率

高估
5 年均值 P/S
1.45
当前P/S
3.11
高估
2.95
低估
-0.04

事件时间线

2026-10-16 (ET)

11:30:00

Picard Medical Inc Trading Halted

2026-10-15 (ET)

15:30:00

Picard Medical Inc Trading Halted

2026-10-05 (ET)

10:30:00

Picard Medical Inc Trading Halted

2026-08-25 (ET)

10:00:00

Picard Medical Inc Trading Halted

2026-07-21 (ET)

21:00:00

Picard Medical Approves 1-for-50 Reverse Stock Split

资讯

PMI 常见问题 —— 由 Alphio AI 解答

Picard Medical, Inc. is a holding company that owns a 100% interest in SynCardia Systems, LLC (SynCardia). SynCardia is a medical technology company that manufactures and sells the only United States Food and Drug Administration (FDA) and Health Canada-approved implantable total artificial heart (SynCardia TAH). The SynCardia TAH is a biventricular replacement device that consists of the SynCardia TAH implant, an external pneumatic driver that delivers precisely calibrated pulses of air to drive the implant, and drivelines that connect the driver to the implant. The SynCardia TAH implant is a system that consists of two independent artificial ventricles which are powered by an external pneumatic driver. Each artificial ventricle is made of a semi-rigid polyurethane housing and a rigid polyurethane base, with a four-layer flexible polyurethane diaphragm separating the blood chamber from the air chamber. It operates in the Healthcare sector.

Picard Medical Inc (PMI) appears to be a good buy right now due to its recent revenue growth of 39% in Q2 2026, reaching approximately $3.0 million, and a notable improvement in gross margin to 20.9%. However, the main risk is the ongoing net loss of approximately $5.7 million for the same quarter, which indicates that while the company is improving, it still faces significant financial challenges.

暂无帖子

注册或登录后参与讨论

相关文章

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易